Genpharmasec Ltd Stock Price Today (NSE: GENPHARMA)
Fundamental Score
Genpharmasec Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Genpharmasec Ltd share price today is ₹0.78, down 7.69% on NSE/BSE as of 30 March 2026. Genpharmasec Ltd (GENPHARMA) is a Small-cap company in the Trading & Distributors sector with a market capitalisation of ₹81.95 (Cr). The 52-week high for GENPHARMA share price is ₹2.38 and the 52-week low is ₹0.82. At a P/E ratio of 149.01x, GENPHARMA is currently trading above its industry average P/E of 35.45x. The company has a Return on Equity (ROE) of 1.90% and a debt-to-equity ratio of 0.17.
Genpharmasec Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Genpharmasec Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Genpharmasec Share Price Analysis: A ROCE Efficiency Perspective
In the dynamic world of Trading & Distributors, efficient capital allocation is paramount. Companies that excel at generating returns on invested capital often outperform their peers. This analysis examines the recent performance of Genpharmasec share price, currently trading at ₹1.13, through the lens of Return on Capital Employed (ROCE). We observe a Price-to-Earnings (PE) ratio of 149.01 and an ROCE of 3.35% for Genpharmasec Ltd.
A key indicator for investors is the ROCE, which measures a company's profitability relative to the capital it employs. Genpharmasec Ltd’s ROCE of 3.35% suggests that for every ₹100 invested, the company generates a return of ₹3.35. This figure should be considered in the context of its industry peers. Compared to companies like
Prismx Global Ventures Ltd, a detailed analysis of management quality and capital allocation strategies would shed light on the reasons for the difference in performance metrics between the companies. Such comparative study would require a deep dive into management's track record and their ability to navigate the competitive landscape.The relatively low ROCE of 3.35% may impact the company’s economic moat, which is its ability to maintain a competitive advantage over rivals. A higher ROCE generally signifies a stronger moat as it implies superior efficiency and profitability. With a lower ROCE, Genpharmasec Ltd. might face challenges in reinvesting in its business, defending its market share, and generating sustainable long-term growth. This, in turn, could affect its ability to attract and retain investors.
This observational analysis is part of a broader 80-parameter fundamental audit conducted and verified by Sweta Mishra, focusing on key financial ratios and market positioning. Further research into operational efficiency, debt levels, and sector-specific dynamics is crucial for a comprehensive understanding of Genpharmasec Ltd's long-term prospects. A deeper investigation into the company's operational efficiency is suggested for more clarity.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Genpharmasec Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GENPHARMA across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Revenue Growth (441.29%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (1.90%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.35%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 149.01x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-268.57%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Low Promoter Commitment (29.98%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Genpharmasec Ltd Financial Statements
Comprehensive financial data for Genpharmasec Ltd including income statement, balance sheet and cash flow
About GENPHARMA (Genpharmasec Ltd)
Genpharmasec Ltd is a dynamic enterprise operating at the intersection of pharmaceutical distribution and strategic investments. The company facilitates the seamless flow of vital ...pharmaceutical resources, connecting manufacturers with healthcare providers across the Indian landscape. Genpharmasec functions as a key logistical partner, ensuring the reliable and efficient delivery of medical necessities to where they are needed most. Beyond simply moving products, Genpharmasec is deeply engaged in understanding and navigating the complexities of the pharmaceutical market, adapting to its ever-evolving demands and regulatory framework. This proactive approach allows them to capitalize on emerging opportunities and provide tailored solutions to both suppliers and customers, fostering strong and enduring relationships within the healthcare ecosystem. A critical component of Genpharmasec's operations lies in its specialized distribution of diagnostic pharmaceutical equipment. Notably, this includes sophisticated tools like i-STAT analyzers and associated cartridges, essential for rapid blood analysis in critical care settings. By making these advanced diagnostic tools readily available, Genpharmasec directly contributes to the enhancement of patient care within Intensive Care Units (ICUs) and other acute care facilities. Their commitment to supplying cutting-edge diagnostic technology reflects a dedication to improving the speed and accuracy of medical assessments, enabling healthcare professionals to make informed decisions and deliver timely interventions. This targeted approach to diagnostic equipment distribution highlights Genpharmasec's focus on meeting the specialized needs of critical care environments. Furthermore, Genpharmasec Ltd engages in strategic investment and trading within the securities market. This facet of the company's activities demonstrates a diversification strategy aimed at generating value and strengthening its overall financial position. By actively participating in the financial markets, Genpharmasec seeks to optimize its resources and enhance its ability to support its core pharmaceutical distribution operations. This financial acumen enables the company to reinvest in its infrastructure, expand its product portfolio, and explore new avenues for growth and innovation. The synergy between its pharmaceutical distribution expertise and its investment activities positions Genpharmasec as a multifaceted organization with a long-term vision for sustainable success.
Company Details
Key Leadership
Latest News
GENPHARMA Share Price: Frequently Asked Questions
What is the current share price of Genpharmasec Ltd (GENPHARMA)?
As of 30 Mar 2026, 12:07 pm IST, Genpharmasec Ltd share price is ₹0.78. The GENPHARMA stock has a market capitalisation of ₹81.95 (Cr) on NSE/BSE.
Is GENPHARMA share price Overvalued or Undervalued?
GENPHARMA share price is currently trading at a P/E ratio of 149.01x, compared to the industry average of 35.45x. Based on this relative valuation, the Genpharmasec Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of GENPHARMA share price?
The 52-week high of GENPHARMA share price is ₹2.38 and the 52-week low is ₹0.82. These values are updated daily from NSE/BSE price data.
What factors affect the Genpharmasec Ltd share price?
Key factors influencing GENPHARMA share price include quarterly earnings growth (Sales Growth: 441.29%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Genpharmasec Ltd a good stock for long-term investment?
Genpharmasec Ltd shows a 5-year Profit Growth of N/A% and an ROE of 1.90%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.17 before investing in GENPHARMA shares.
How does Genpharmasec Ltd compare with its industry peers?
Genpharmasec Ltd competes with major peers in the Trading & Distributors. Investors should compare GENPHARMA share price P/E of 149.01x and ROE of 1.90% against the industry averages to determine competitive standing.
What is the P/E ratio of GENPHARMA and what does it mean?
GENPHARMA share price has a P/E ratio of 149.01x compared to the industry average of 35.45x. Investors pay ₹149 for every ₹1 of annual earnings.
How is GENPHARMA performing according to Bull Run's analysis?
GENPHARMA has a Bull Run fundamental score of 11/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does GENPHARMA belong to?
GENPHARMA operates in the Trading & Distributors industry. This classification helps understand the competitive landscape and sector-specific trends affecting Genpharmasec Ltd share price.
What is Return on Equity (ROE) and why is it important for GENPHARMA?
GENPHARMA has an ROE of 1.90%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Genpharmasec Ltd generates profits from shareholders capital.
How is GENPHARMA debt-to-equity ratio and what does it indicate?
GENPHARMA has a debt-to-equity ratio of 0.17, which indicates conservative financing with low financial risk.
What is GENPHARMA dividend yield and is it a good dividend stock?
GENPHARMA offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Genpharmasec Ltd shares.
How has GENPHARMA share price grown over the past 5 years?
GENPHARMA has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in GENPHARMA and why does it matter?
Promoters hold 29.98% of GENPHARMA shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Genpharmasec Ltd.
What is GENPHARMA market capitalisation category?
GENPHARMA has a market capitalisation of ₹82 crores, placing it in the Small-cap category.
How volatile is GENPHARMA stock?
GENPHARMA has a beta of N/A. A beta > 1 suggests the Genpharmasec Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is GENPHARMA operating profit margin trend?
GENPHARMA has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is GENPHARMA quarterly performance?
Recent quarterly performance shows Genpharmasec Ltd YoY Sales Growth of 441.29% and YoY Profit Growth of -268.57%.
What is the institutional holding pattern in GENPHARMA?
GENPHARMA has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Genpharmasec Ltd stock.